ConferenceAgendaMap / DirectionsContact UsNewsRegister Now


Monday, February 12





Welcome and Introduction

8:00 am

Robin R. Young, CFA

Market forecast for the commercialization of stem/progenitor cells in four principal markets: cardio, ortho, oncology and urology.

Cardio Presentations

8:20 am

Ed Field, President

Aldagen is a clinical-stage regenerative medicine company developing and commercializing products to treat vascular and degenerative diseases. The company’s proprietary products can identify and isolate potent, highly effective adult stem and progenitor cells which can be quickly administered to regenerate or repair tissue.


8:35 am

Chris Calhoun, CEO

Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue.


8:50 am

Howard Leonhardt, CEO

Bioheart, Inc. is focused on the discovery, development and commercialization of cell-based therapy products for the treatment of cardiovascular diseases.


9:05 am

Don Brown, CEO

Arteriocyte’s focus is stem cell-based therapies to treat ischemia in patients with coronary artery disease, peripheral vascular disease, stroke, and renal ischemia.

Ortho Presentations

9:20 am

Ray Linovitz, MD

Trinity® relies on proprietary technology to produce a viable bone matrix product containing stem cells.


9:35 am

Stewart Craig, PhD

Progenitor Cell Therapy (PCT) is a client-based cell therapy services company that supports the development and commercialization of cellular therapies. PCT provides cGMP-compliant cell manufacturing, development, and consulting services that address regulatory, financial, technical, process, and quality system strategies. Services include a full spectrum of support and consulting related to process and product development, validation, due diligence evaluations, tissue collection, processing, and storage, product manufacturing, distribution and transportation.


9:50 am

Sheldon Schaffer, PhD

Aastrom Biosciences, Inc. is developing autologous cell products based on its proprietary Tissue Repair Cell (TRC) technology. The company used TRC-based products in approximately 230 patients, which are in active clinical trials for applications, such as bone regeneration, including long bone fractures and spine fusion

_ Oncology Presentations

10:05 am

Hassan Salari, PhD

Chemokine Therapeutics Corp. discovers and develops peptide analogs of chemokines for cancer treatment, and immune system recovery.


10:20 am

David Bonner , CEO

Regenetech Inc.’s technology allows the cells to potentially eliminate the need for bone marrow transplants. If successful, it may reduce the side effects of chemotherapy.


10:35 am

Morey Kraus, CTO

ViaCell is developing proprietary stem cell products. CB001, its lead cord blood derived stem cell therapy product, is being developed for patients affected by a variety of cancers.


10:50 am

Alan K. Smith, PhD

Cognate BioServices, Inc. was formed to provide full commercialization support to companies developing varied cellular technologies.


11:05 am_




Other Indications

11:20 am

Anne Faulkner Schoemaker, CEO

Neuronyx is a pioneer in the use of adult bone marrow-derived somatic cells (hABM-SC) and we believe the first company to test the ability of directly delivered cells to repair damaged cardiac tissue in patients who have suffered a heart attack.


11:35 am

Jane Lebkowski, PhD

Geron Corporation develops and commercializes cell-based therapies derived from its human embryonic stem cell platform for applications in various diseases. The company intends to use human embryonic stem cell technology to enable the development of transplantation therapies by providing starting material for the manufacture of cells and tissues.


11:50 am

Nicholas J. Seay, COO

Cellular Dynamics provides cardiac drug toxicity testing at present and plans to develop additional cellular products for pharmaceutical and biotechnology companies to assist in the development of safer and more effective drugs.

12:05 pm

Zen Chu, President

3DM develops a new class of biologically-inspired polypeptide biomaterials which have been discovered and tested in the context of cell culture, stem cell biology and tissue engineering. PuraMatrix™ are fine nanofibers that create a 3-dimensional porous scaffold.


12:20 pm

Nicholas J. Seay, COO

The company will initially concentrate on process improvements in the manufacture and delivery of embryonic stem cell derived red blood cells and platelets. The company intends to develop techniques to permit industrial-scale manufacturing of embryonic stem cell derived blood products for human clinical use.


12:35 pm

Michael West, MD

Advanced Cell Technology is a biotechnology company focused on developing and commercializing human stem cell technology for regenerative medicine.

Lunch Break



Panel Discussion: Roy Fiebiger, Managing Partner, Sanford Rose Associates
“Current Concepts in Stem Cell Company Management”

Dr. Marc Hedrick, President - Cytori Therapeutics

Morey Kraus, VP & CTO - ViaCell Inc.

Earl Fender, VP & General Manager - Osiris Therapeutics Inc.


1:30 pm

Michael Haider, CEO

BioE provides innovative Cell Biologics technologies for the biomedical industry.  The most recent commercial cell biologics product is the multi-lineage progenitor cell™ (MLPC™).


1:45 pm

Alan Lewis, PhD

Novocell is completing a Phase I/II study to determine the safety and efficacy of human pancreatic islets encapsulated with polyethylene glycol (PEG) and implanted into patients with Type I diabetes.


2:00 pm

Michel F. Levesque, MD

NeuroGeneration is a clinical stage biotechnology company with neural stem cell products targeting neurological disorders caused by cell loss or injury.


2:15 pm

BJ Lehmann

Athersys is a biopharmaceutical company engaged in the development and commercialization of cell based therapeutic products that treat significant and life-threatening diseases.


2:30 pm

Madhusudan Peshwa, VP of Research & Development

Maxcyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies.


2:45 pm

Michael Hunt, CEO

Reneuron has leading edge, proprietary somatic stem cell technologies from which the company is developing into groundbreaking cell therapy products. Reneuron’s focus is on cell therapy treatments designed to reverse the effects of major diseases such as stroke, diabetes and diseases of the retina.


3:00 pm

Allen Davidoff, PhD

Stem Cell Therapeutics’ lead program, NTx™- 265, represents a new conceptual approach in the struggle to develop effective stroke treatments. Stem Cell Therapeutics is currently enrolling a phase IIa open label study to establish the safety of Ntx™-265 in stroke patients and to explore potential efficacy endpoints in advance of a phase IIb currently under design..


3:15 pm

C. Randal Mills, PhD, President and CEO

Osiris Therapeutics, Inc. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel® for regenerating bone in orthopedic indications. The Company’s pipeline of internally developed biologic drug candidates under evaluation includes Prochymal™, in Phase III trials for both GvHD and Crohn's disease, Chondrogen™ for regenerating cartilage in the knee and preventing osteoarthritis, and Provacel™, for repairing heart tissue following a heart attack.


3:45 pm

Luc Dochez, VP of Business Development

TiGenix is a venture-backed, private biotech company that was created as a spin-off from the universities of Leuven and Gent in Belgium. The Company operates at the cutting edge of regenerative medicine and focuses its research and development on innovative local treatments for damaged and osteoarthritic joints


4:00 pm

Robin R. Young, CFA


Tuesday, February 13



Speaker's Topic

8:00 am - 8:05 am

Robin Young
President RRY Publications

Welcome and Introductions

8:05 am - 8:30 am

Arnold Caplan, PhD
Professor of Biology and General Medicine Sciences (Oncology) Case Western Reserve University

Cell Therapy: MSCs as Regulated Drugstores

8:30 am - 8:45 am

LIVE Stem Cell Surgery

Stem Cells as an adjunct to Spine Fusion Surgery.
Scripps Memorial Hospital in Encinitias
Dr. Timothy Peppers

8:45 am - 9:05 am

Mark Lorenz, MD
Board Certified Orthopedic Surgeon
Specializing in; Disorders of the Spine Examiner American Board ,Orthopaedic Spine Surgery, Editorial Reviewer Spine Journal

Practical Clinical Experience using Stem Cells in Spine Surgery

9:10 am - 9:30 am

LIVE Stem Cell Surgery

Stem Cells as an adjunct to Spine Fusion Surgery.
Scripps Memorial Hospital In Encinitas
Dr. Timothy Peppers

9:30 am - 9:50 am

Hans Jorg Meisel,MD, PhD
Chairman, Dept. of Neurosurgery
Bergmannstrost Merseburger Germany

Cell therapies as an Opportunity for Disc Repair

9:55 am - 10:15 am

Phillipe Hernigou, MD, PhD
Professor and Chairman Orthopaedic Surgery, Hospital Henri Mondor Paris, Creteil, France

Treatment of Delayed Unions and Osteonecrosis of the hip, shoulder or knee with stem cells

10:20 am - 10:40 am

Thomas Vangsness, MD
Professor of Orthopedics
University of Southern California School of Medicine
Member: editorial boards of the Journal of Arthroscopy and The Journal of Knee Surgery

Results of the Chondrogen Trial to Repair Meniscus Cartilage



11:00 am - 11:20 am

Hans-Georg Klingemann
Director, Bone Marrow and Hematopoietic Stem Cell Transplantation Program
Tuft New England Medical Center
Prochymal Presentation
‘Mesenchymal Stem Cell and Inflammatory Disease”

Stem Cells to Treat Graft versus Host Disease

11:25 am - 12:00 noon

Scott Boden, MD, Panel Moderator
Professor of Orthopaedics, Director of The Emory Spine Center
Orthopedic Surgeon Atlanta, Georgia
Arnold Caplan PhD
Hans Jorg Meisel, MD, PhD
Thomas Vangsness MD

Therapeutic use of stem cells.
What do we know and where do we go from here?





Osiris Therapeutics, Inc. Cytori Therapeutics Blackstone Medical, Inc.BIOCOM